FMP

FMP

Enter

OGEN - Oragenics, Inc.

Financial Summary of Oragenics, Inc.(OGEN), Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engag

photo-url-https://financialmodelingprep.com/image-stock/OGEN.png

Oragenics, Inc.

OGEN

AMEX

Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

1.23 USD

-0.025 (-2.03%)

About

ceo

Mr. Charles L. Pope CPA

sector

Healthcare

industry

Biotechnology

website

https://www.oragenics.com

exchange

AMEX

Description

Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials rela...

CIK

0001174940

ISIN

US6840235005

CUSIP

684023500

Address

4902 Eisenhower Boulevard

Phone

813 286 7900

Country

US

Employee

6

IPO Date

Feb 25, 2004

Summary

CIK

0001174940

Exchange

AMEX

Industry

Biotechnology

Sector

Healthcare

CUSIP

684023500

ISIN

US6840235005

Country

US

Price

1.23

Beta

0.29

Volume Avg.

96.94k

Market Cap

5.51M

Shares

-

52-Week

1.16-7.74

DCF

1.41

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.27

P/B

-

Website

https://www.oragenics.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest OGEN News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep